Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05739435 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
A Phase 2 study of Plaque Psoriasis, sponsored by Alumis.
- Active
- Registry status
- Phase 2
- Development phase
- 165
- Enrollment target
- 20
- Study locations
NCT05739435 is a Phase 2 study of Plaque Psoriasis that is active but no longer recruiting, run by Alumis. The registered enrollment target is 165 participants, below the 412-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (60% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT05739435, a Phase 2 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Alumis.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 165 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
Conditions Studied
Interventions
- DRUG ESK-001
Study Locations (20)
California
- Investigator Site #1021 - Encinitas
- Investigator Site #1018 - Los Angeles
- Investigator Site #1007 - Santa Monica
- Investigator Site #1002 - Sherman Oaks
Florida
- Investigator site # 1030 - Fort Lauderdale
- Investigator Site #1025 - Hialeah
- Investigator site # 1028 - Miami
- Investigator Site # 1013 - Tampa
Georgia
- Investigator Site #1035 - Macon
- Investigator Site #1043 - Sandy Springs
Indiana
- Investigator Site # 1011 - Columbus
- Investigator Site #1027 - South Bend
Alabama
- Investigator Site # 1029 - Birmingham
Arizona
- Investigator Site #1001 - Phoenix
Arkansas
- Investigator Site # 1023 - Rogers
Illinois
- Investigator Site #1005 - Rolling Meadows
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 165 participants |
| Start Date | 2023-01-17 |
| Est. Completion | 2026-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05739435
The ClinicalTrials.gov registry entry for NCT05739435 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 165 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 412-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (60% lower). The listed sponsor is Alumis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 1 intervention - of which ESK-001 is the first listed.
NCT05739435 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT05739435 about?
NCT05739435 is a clinical study titled "Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis". This is a multi-center, open-label extension (OLE) study in patients with plaque psoriasis who have completed their participation in a previous plaque psoriasis study of ESK-001.
What is the current status of trial NCT05739435?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 165 participants. The study started on 2023-01-17. Estimated completion is 2026-12-30.
What conditions does trial NCT05739435 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT05739435?
The interventions under investigation include: ESK-001 (DRUG).
Who is sponsoring clinical trial NCT05739435?
This trial is sponsored by Alumis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05739435 being conducted?
This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
RECRUITING · Phase 2
-
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
RECRUITING · Phase 2
-
ORKA-001 Versus Placebo in Patients With Moderate-to-Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 2
-
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
COMPLETED · Phase 2
-
Pharmacokinetics of 122-0551 and Its Effects on Adrenal Suppression
COMPLETED · Phase 2
-
Maximal Use Study of Tapinarof Cream, 1% in Adults With Extensive Plaque Psoriasis
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.